HCM Risk-SCD
ورودیهای بالینی بیمار
حداقل ۱۶ — حداکثر ۱۱۰ • واحد: years
حداقل ۱۰ — حداکثر ۴۰ • واحد: mm
حداقل ۱۵ — حداکثر ۷۰ • واحد: mm
حداقل ۰ — حداکثر ۲۰۰ • واحد: mmHg
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–3.999
- Intermediate Risk4–5.999
- High Risk6–100
The HCM Risk-SCD calculates stratifying cardiovascular risk, predicting thromboembolic events, or guiding therapeutic interventions. Key inputs include age. Scores guide initiating guideline-directed medical therapy, antithrombotic or anticoagulant regimens, or urgent coronary angiography. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.
Clinical Indication
The HCM Risk-SCD is indicated for bedside clinical practice to support Estimates 5-year risk of sudden cardiac death in patients with hypertrophic cardiomyopathy. Helps determine need for implantable cardioverter defibrillator (ICD) in HCM patients.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Adult patients presenting with suspected or established coronary artery disease, cardiac arrhythmias, congestive heart failure, or valvular heart defects. Clinical application is indicated across Emergency department, cardiac care unit (CCU), cardiac catheterization laboratory, and outpatient cardiology clinics.
Limitations & Contraindications
In hemodynamically unstable cardiogenic shock, cardiac arrest, or refractory acute coronary syndromes, immediate resuscitation and coronary angiography supersede scoring.
Clinical Pearls & Action Plan
Continuous 12-lead ECG monitoring, serial cardiac troponin measurements, and echocardiographic evaluation align with ESC/ACC/AHA clinical practice guidelines.
Prognostic Index = 0.15939858*(Max wall thickness) - 0.00294271*(Max wall thickness)² + 0.0259082*(LA diameter) + 0.00446131*(Max LVOT gradient) + 0.4583082*(Family history SCD) + 0.82639195*(NSVT) + 0.71650361*(Unexplained syncope) - 0.01799934*(Age); 5-year SCD risk (%) = 1 - 0.998^exp(Prognostic Index)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Age at evaluation in years(years) |
| family_history_scd | string | Yes | History of sudden cardiac death in ≥1 first degree relatives <40 years of age or SCD in any relative with confirmed HCM at any age |
| max_wall_thickness | float | Yes | Maximum wall thickness - greatest thickness in anterior septum, posterior septum, lateral wall, and posterior wall of the LV measured by echocardiography(mm) |
| left_atrial_diameter | float | Yes | Left atrial diameter determined by M-Mode or 2-D echocardiography in parasternal long axis view(mm) |
| max_lvot_gradient | float | Yes | Maximal left ventricular outflow tract gradient determined at rest and with Valsalva provocation (peak instantaneous gradient)(mmHg) |
| nsvt | string | Yes | Non-sustained ventricular tachycardia - ≥3 consecutive ventricular beats at a rate of ≥120 bpm and <30 s in duration on Holter monitoring |
| unexplained_syncope | string | Yes | History of unexplained syncope at or prior to evaluation |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–3.999 | Low Risk | Low 5-year SCD risk |
| 4–5.999 | Intermediate Risk | Intermediate 5-year SCD risk |
| 6–100 | High Risk | High 5-year SCD risk |
Evidence-Based References (EBM)
- O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20. doi: 10.1093/eurheartj/eht439.DOI: 10.1093/eurheartj/eht439
- Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014 Oct 14;35(39):2733-79. doi: 10.1093/eurheartj/ehu284.DOI: 10.1093/eurheartj/ehu284
- O'Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). Circulation. 2018 Mar 6;137(10):1015-1023.